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  21 
Synopsis 22 
Objectives: To determine the effectiveness of live attenuated influenza vaccine (LAIV) in reducing 23 
amoxicillin prescribing in preschool children in primary care. 24 
Materials and methods: We used The Health Improvement Network (THIN), a large primary care 25 
database from the United Kingdom. We included children aged two to four years old at the start of 26 
either the 2013/14 or the 2014/15 winter season, with at least one amoxicillin prescription between 27 
September and May, irrespective of LAIV vaccination status. We used the self-controlled case series 28 
method to estimate influenza vaccine effectiveness (VE). 29 
Results The total study sample included 33,137 children from 378 general practices during the two 30 
winter seasons. Of these children, 43.4% with at least one amoxicillin prescription had been 31 
vaccinated. The rate of amoxicillin prescribing was significantly reduced during periods of influenza 32 
vaccine immunity. The associated VE for amoxicillin prescribing was 12.8% (95% confidence interval 33 
(CI) 6.9%, 18.3%) in 2013/14 and 14.5% (9.6%, 19.2%) in 2014/15. Given a VE of 14.5%, we estimated 34 
that amoxicillin prescribing could have been reduced by 5.6% if LAIV uptake in two to four year old 35 
children increased to 50% in the 2014/15 winter season. 36 
Discussion: Influenza vaccination of young children may contribute to a reduction in prescribing of 37 
amoxicillin, one of the most commonly prescribed antibiotics in primary care. Immunisation through 38 
the universal UK influenza vaccination programme should be encouraged in this age group. Further 39 
studies are required to confirm the size of the effect. 40 
  41 
Introduction  42 
Influenza causes a major burden on primary and secondary care services and families every winter in 43 
temperate countries.1-3  Although influenza rarely results in secondary bacterial infection4 it is linked 44 
with excess antibiotic prescribing in children.5 The symptoms of influenza are diffuse6 and may be 45 
difficult to distinguish from bacterial infections,7 particularly in primary care where the majority of 46 
influenza cases present but diagnostic sampling is not widely available. Overuse of antibiotics is a 47 
major public health challenge due to increased antibiotic resistance.8 It is therefore of interest to 48 
determine the role of influenza immunisation programmes in reducing antibiotic prescribing.9  49 
Two clinical trials have examined the effect of influenza vaccination on antibiotic prescribing; one of 50 
live attenuated influenza vaccine (LAIV) in adults,10 the other of inactivated influenza vaccine (IIV) in 51 
children aged six months to nine years.11 The size of the effect in the paediatric trial was one less 52 
antibiotic prescription per child per season. Both these studies are now over 15 years old and 53 
antibiotic prescribing practices have changed over time.  54 
A new policy of offering annual vaccination with intranasal LAIV to all children aged two to 16 years 55 
in the United Kingdom began in September 2013.12 In 2015/16, between 34% and 57% (varying by 56 
UK country) of preschool children aged two to four years were vaccinated in primary care. 13,14  57 
Whether LAIV reduces antibiotic prescribing is of interest to clinicians, parents and policy makers 58 
evaluating the impact of the new influenza vaccination programme. There are no trials of the effect 59 
of LAIV on antibiotic prescribing in children, and further trials are unethical in the UK due to the 60 
recommendation to vaccinate all children. Observational studies comparing vaccinated and 61 
unvaccinated children lead to confounding by indication, since both influenza vaccination and 62 
complications are more common in children with chronic conditions.14,15  63 
We evaluate the effectiveness of LAIV in reducing antibiotic prescribing in preschool children in 64 
primary care in the UK. We focus on prescribing of amoxicillin, indicated for two common 65 
complications of influenza: community acquired pneumonia and (in some children) acute otitis 66 
media. We used a large primary care database and applied the self-controlled case series (SCCS) 67 
methodology16,17 to minimise confounding by indication.  68 
 69 
Methods 70 
Ethics  71 
All data in this study were anonymised. Data collection has been approved by the South East NHS 72 
Multicentre Research Ethics Committee. The analyses presented here were approved by the 73 
Scientific Review Committee of the data providers (QuintilesIMS), study reference number SRC 14–74 
004. 75 
Study design: The Self Controlled Case Series method 76 
This method was originally developed to examine vaccine safety but has now been applied in a range 77 
of pharmacoepidemiological studies, including for evaluating the effect of influenza vaccination on 78 
asthma18,19 and chronic obstructive pulmonary disease (COPD) exacerbations.20 The method includes 79 
only individuals who have had the outcome of interest (cases), and compares the incidence rate 80 
within each case of the outcome of interest during a time-limited exposed period (eg. the period of 81 
vaccine protection) to rates during unexposed, or ‘baseline’ periods. Thus, the question is ‘when’ 82 
rather than ‘who’ experience the events. Since the analyses are conditional on each case, any 83 
characteristics such as gender or prevalence of chronic conditions which do not vary during the 84 
study period are inherently controlled for.17 Any time-varying factors, like age or seasonal variation 85 
need to be adjusted for in the analyses. 86 
Data source 87 
We used The Health Improvement Network (THIN) primary care database for this study.21 THIN 88 
contains anonymised longitudinal data on diagnoses, prescriptions, vaccinations and demographic 89 
information for around 6% of the UK population. THIN is approximately representative of the 90 
general UK population in terms of demographic characteristics, and primary care practices 91 
contributing to THIN are representative of all UK general practices in terms of prescribing and 92 
consultation rates.22,23 Influenza vaccination uptake rates in THIN, including of LAIV, has been found 93 
to be similar to uptake figures published by UK public health agencies.24,25 Data are entered by the 94 
general practitioner (GP, primary care clinician) during patient consultations. Prescriptions are 95 
recorded in THIN using drug codes which map to the British National Formulary.26  96 
Study period and population 97 
We examined LAIV effectiveness during the first two winter seasons of the universal childhood 98 
influenza vaccination programme: 2013/14 and 2014/15. Separate analyses were carried out for 99 
each season since the influenza strains contained in the influenza vaccine were well matched to the 100 
circulating strains in the 2013/14 season but less so in 2014/15.12 Influenza A/H1N1 was the 101 
dominant strain in 2013/14 and A/H3N2 in 2014/15. Children were eligible to be vaccinated from the 102 
1st September each year. We defined each season from the first Monday in September until the 18th 103 
May 2014 and 17th May 2015 (Sunday of week 20) respectively, when active surveillance for 104 
respiratory infections by UK public health agencies end.27  105 
Children were considered eligible for inclusion in one or both study cohorts if they were registered 106 
with a THIN practice on the 1st September 2013 or 2014, met the age criteria for the target group to 107 
receive LAIV in primary care in that respective season (children aged two to three years inclusive on 108 
the 31st August 2013 for 2013/14 and children aged two to four years inclusive on the 31st August 109 
2014 in 2014/15), and had at least one amoxicillin prescription during either of the two study 110 
periods. That is, children were included in the analysis for 2013/14 if they had at least one 111 
amoxicillin prescription in 2013/14; and in the analysis for 2014/15 if they had at least one 112 
amoxicillin prescription in 2014/15. 113 
Children were followed from the start to the end of the study period or until they deregistered from 114 
the practice. Infections leading to a prescription of amoxicillin are likely to cluster within families. In 115 
order to ensure independence of outcomes we randomly selected one child per family (identified via 116 
the family number in THIN24) in the eligible age range for inclusion in the cohort.24  117 
We included both vaccinated and unvaccinated cases. Since estimation of the relative risk of 118 
amoxicillin prescribing is within children only, unvaccinated children do not contribute to the 119 
estimation of the vaccine effect (only to estimation of the other time varying covariates in the 120 
model). The vaccinated periods are long in relation to the observation period (see below). It would 121 
be impossible to distinguish between seasonal variation and vaccine effects during periods when 122 
almost all cases have been vaccinated (as would happen during early spring). Therefore including 123 
unexposed (ie. unvaccinated) cases makes it possible to more accurately adjust for seasonal 124 
effects.17  125 
Outcome 126 
The outcome in this study was amoxicillin prescriptions. Amoxicillin is indicated for community 127 
acquired pneumonia and acute otitis media in children who are systemically unwell, at high risk of 128 
complications, or with persisting symptoms. Petersen et al28 found that only 50-60% of antibiotic 129 
prescriptions had an associated indication recorded on the same day. Therefore we considered any 130 
prescription for amoxicillin irrespective of the indication. A child may receive more than one 131 
amoxicillin prescription each season. One of the assumptions of the SCCS method is that outcomes 132 
are independent, conditional on the time-varying covariates.16,17 In order to meet this assumption 133 
we created prescribing episodes and assumed that all amoxicillin prescriptions in a 30-day period 134 
were associated with the same infection. Separate prescription episodes were assumed to be 135 
independent of each other. Only the first prescription in each 30 day period was included.  136 
Influenza vaccination status  137 
The exposure variable was receipt of LAIV. We used a code list developed for a previous study to 138 
identify children who have been vaccinated using LAIV and their date of vaccination each season.24 139 
Children with severe immunosuppression, asthma, or active wheezing are recommended to receive 140 
IIV rather than LAIV. Children receiving at least one dose of IIV was excluded from the analyses for a 141 
particular season. Children who are not in a clinical risk group (94.5% of preschool children 24) are 142 
recommended to receive one dose of LAIV. We therefore did not have a sufficient number of cases 143 
to examine the effectiveness of two versus one dose of LAIV. Children who had received two doses 144 
of vaccine were included in the study, but only the effect of one dose was assessed, that is, we did 145 
not further split the exposure period into subperiods following the first dose and the second dose.  146 
LAIV vaccination status was treated as a time-varying covariate. The vaccination exposure periods 147 
are summarised in Figure S1. There is little evidence regarding how long influenza vaccine immunity 148 
lasts in children.29-31 We assumed that vaccine-induced immunity lasts for six months in our baseline 149 
scenario, then varied assumptions about vaccine protection in sensitivity analyses.  150 
Parents of children who required amoxicillin are likely to delay vaccination until symptoms have 151 
improved. In order for the SCCS model to be valid, the outcome of interest should not influence the 152 
exposure (LAIV receipt). Therefore, we included a `pre-vaccination’ period in the analyses, lasting 153 
from the day of vaccination-14 to the day of vaccination-1. We assumed that vaccine induced 154 
immunity begins at 14 days after vaccination, in line with previous studies.31-33 We therefore 155 
excluded a 14-day period after the date of vaccination. Excluding the immediate 14-day post-156 
vaccination period also allowed us to take into account that amoxicillin prescription rates are likely 157 
to remain low immediately after vaccination, since children should be in good health at the time of 158 
vaccination. 159 
Seasonality and influenza circulation periods 160 
A number of different virus infections, including influenza, lead to amoxicillin prescribing in children 161 
during winter seasons. To allow for underlying seasonality of amoxicillin prescriptions (whatever the 162 
causative pathogen), we split the follow-up time into weeks of the winter season, and adjusted for 163 
week as a factor variable in the statistical models. By using this approach, we assumed that the 164 
underlying seasonality (i.e. timing) of respiratory virus circulation (including influenza) is the same 165 
among vaccinated and unvaccinated children. In terms of vaccine effects, the SCCS model tests 166 
whether the relative incidence is lower in vaccinated versus unvaccinated periods, adjusted for 167 
underlying seasonality of amoxicillin prescribing.  168 
Since we hypothesised that LAIV would only be effective in preventing amoxicillin prescribing during 169 
periods when influenza virus was circulating in the community, we further split the follow-up time 170 
into influenza circulating and non-circulating periods and included this variable as a time varying 171 
covariate in the SCCS model. In the 2013/14 season, influenza circulated between end of December 172 
2013 (week 52) and end of March (week 14) according to sentinel swabbing schemes run by Public 173 
Health England (PHE).34 In 2014/15, influenza circulation was established by week beginning of 174 
December (week 49) and continued until beginning of April (week 15).27  175 
Statistical analyses  176 
Only children who had had at least one amoxicillin prescription were included in the analyses. We 177 
describe their characteristics in terms of age at cohort inception, sex, influenza vaccination status, 178 
and whether they were in a clinical risk group due to underlying chronic conditions, and therefore 179 
considered to be at increased risk of influenza-related complications, in each season. We used a 180 
code list used by PHE to measure vaccination uptake in primary care to define whether a child was in 181 
a clinical risk group.35 A child was classified as being in a clinical risk group if they had any code 182 
recorded up to one year before the start of each winter season.  183 
We plotted the proportion of cases who had been vaccinated and the number of prescriptions each 184 
week to assess the overlap in timing between exposure and outcome events. The SCCS models were 185 
fitted using a conditional Poisson regression model. Vaccine effectiveness (VE) was estimated as  186 
𝑉𝐸 = 1 − 𝐼𝑅𝑅 187 
where the IRR is the relative rate ratio of amoxicillin prescribing in vaccinated periods, relative to 188 
unvaccinated periods, estimated by the fully adjusted SCCS model.  189 
Statistically significant VE in preventing amoxicillin prescriptions was defined as a Wald test p-190 
value<0.05. Separate models were fitted for each of the two seasons. We adjusted for single years of 191 
age (2, 3, 4 and 5 years) as a categorical variable, active influenza circulation and week number as 192 
time varying covariates.  193 
We conducted sensitivity analyses to determine the impact of changing assumptions about the 194 
effect of age and the duration of vaccination protection on VE estimates: 195 
1) restricting analyses to period of active influenza circulation only (scenario 1).  196 
2) increasing the number of age groups to six month age groups rather than single years of age 197 
(scenario 2) 198 
3) assuming vaccine protection lasts for nine months (scenario 3). This means that vaccine 199 
protection extends beyond the end of the study period in this scenario. 200 
4) splitting the six month vaccinated period into two subperiods from 14 days to less than three 201 
months and three months to less than six months after vaccination (scenario 4) 202 
Absolute risk differences cannot be obtained using SCCS. We conducted a simple calculation (not 203 
allowing for herd immunity) to examine the impact of increasing LAIV uptake in two to four year old 204 
children in England beyond current levels, given our estimated VE. First, we obtained the current 205 
number of amoxicillin prescriptions in England by estimating the amoxicillin prescribing rate in two 206 
to four year old children in English THIN practices between September 2014 and April 2015, and 207 
applying these rates to mid-year population estimates from the Office for National Statistics.36 208 
Second, by assuming a constant ratio between VE and uptake, with VE set at the estimated value for 209 
the 2014/15 season, we calculated the expected number of amoxicillin prescriptions 210 
(Prescriptionsexp) for a given scenario of vaccination uptake (VUS) as: 211 
 212 
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛𝑠𝑒𝑥𝑝 =
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛𝑠𝑂𝑏𝑠
1 − 𝑉𝐸
(1 −
𝑉𝑈𝑆𝑉𝐸
𝑉𝑈𝑂𝑏𝑠
) 213 
Where PrescriptionsObs is the observed number of prescriptions in 2014/15, VUObs is observed 214 
vaccination uptake in England in the 2014/15 season (37.6%37), and VE is the vaccine effectiveness 215 
estimated from our study for 2014/15 (see Text S1).  216 
We used Stata 1338 for data management and model fitting and R 3.3.1 for graphical output.  217 
 218 
Results 219 
We identified 90,788 children aged 2 to 3 years in 2013 and 142,273 children aged two to four years 220 
in 2014 (Figure 1). There were 33,137 children from 378 general practices who had at least one 221 
amoxicillin prescription during either of the two seasons. Of these children, 14,368 (43.4%) had 222 
received at least one dose of LAIV in either of the two seasons. Overall, 5,071 children (15.3%) 223 
contributed person time to both study periods. The characteristics of the children in each cohort are 224 
shown in Table 1. The vast majority of children in either cohort had only one prescription episode 225 
each season. 226 
  227 
Half of the vaccines had been administered by the beginning of November in both seasons (Figure 228 
2). Amoxicillin prescriptions displayed several peaks, one in the beginning of December, followed by 229 
two more peaks in mid-February and mid-March. The amoxicillin prescribing rate was lower in the 230 
14 days before and the 14 days after vaccination among the vaccinated cases in both seasons (Figure 231 
S2).  232 
Influenza vaccination was associated with a significant decrease in amoxicillin prescriptions in both 233 
winter seasons. LAIV VE in preventing amoxicillin prescriptions was 12.8% in 2013/14 and 14.5% in 234 
2014/15 (Table 2). Overlapping 95% confidence intervals from the two seasons suggest a similar 235 
effect size. Including the indicator of influenza circulation had negligible effect on influenza VE 236 
estimates in either season.  237 
Subdividing the age groups had negligible effect, whereas restricting the study period to weeks with 238 
active influenza circulation led to a reduction in the number of cases included in the model and 239 
greater variability in the VE estimates. When vaccine protection was assumed to be nine instead of 240 
six months, VE estimates increased in both seasons. When we split the vaccinated period into two 241 
sub-periods, VE point estimates were similar across the two shorter periods. The CIs for the VE 242 
estimates from all sensitivity analyses overlapped with those for the baseline scenario for both 243 
seasons. 244 
We estimate that 626,932 amoxicillin prescriptions were issued to two to four year old children in 245 
England between September 2014 and April 2015. Assuming a VE of 14.5%, only 591,868 amoxicillin 246 
prescriptions would have been prescribed in this season had vaccine uptake been 50% in two to four 247 
year olds (Figure S3) rather than the observed uptake of 37.6%. This amounts to a decrease of 248 
35,064 prescriptions or 5.6%.  249 
 250 
  251 
Discussion 252 
We found a 12.8% to 14.5% reduced rate of amoxicillin prescribing during periods of LAIV-induced 253 
immunity in preschool children. The effectiveness of LAIV in preventing amoxicillin prescribing 254 
episodes was robust to assumptions about the duration of LAIV protection and age effects. 255 
The study included over 30,000 children during the first two seasons of the universal paediatric 256 
influenza vaccination programme in the UK. Only a small proportion of amoxicillin prescriptions are 257 
likely to be prescribed due to influenza complications, and hence any effect of influenza vaccination 258 
is likely to be small. Therefore, a large study is required to detect a vaccination effect. The large 259 
number of cases also allowed us to finely adjust for the seasonal pattern of amoxicillin prescribing 260 
using week of the winter season.  261 
We used the SCCS method to estimate relative amoxicillin prescribing rates during vaccinated and 262 
unvaccinated periods within each child. This is the first time SCCS is used to estimate influenza VE in 263 
children. Use of the SCCS method means any confounding by indication, which often arises in cohort 264 
studies of influenza VE,39 is implicitly controlled for.  265 
We could not examine the effect on prescriptions due to particular symptoms. However, we were 266 
still able to detect a significantly reduced risk of amoxicillin prescribing during periods of LAIV-267 
induced immunity. Since such a small proportion of children received two doses of LAIV, we 268 
examined effectiveness after only one dose. However, these results are relevant to the vast majority 269 
of children in the UK who are only recommended to receive one LAIV dose. 270 
One alternative explanation for our result is that GPs are less likely to prescribe antibiotics to 271 
children who have been vaccinated, if they consider these children to be at lower risk of influenza 272 
complications. However, GPs are advised to decide on antibiotic prescribing based only on the 273 
severity and longevity of symptoms and the presence of chronic conditions, not on whether the 274 
infection is caused by a particular pathogen.40 We therefore consider it unlikely that decisions 275 
regarding antibiotic prescriptions are based on a child’s vaccination status.  276 
Three aspects of our study results were unexpected. First, the effect sizes were similar in the two 277 
seasons under study, despite varying degrees of vaccine strain. We note that significant VE in 278 
preventing laboratory confirmed influenza was still reported by PHE in 2014/15.12 Rather than simply 279 
reducing the incidence of influenza-related complications leading GPs to prescribe amoxicillin, LAIV 280 
may lead to non-specific protection against respiratory infections. Large, randomised clinical trials of 281 
LAIV in young children with antibiotic prescribing as an outcome are required to address this 282 
question.  283 
Second, when we increased the assumed period of LAIV-induced immunity to nine months, the point 284 
estimate of LAIV VE increased. If protection persists beyond six months, inclusion of the 6-9 month 285 
period in the reference category of the base scenario will have caused the effect to be 286 
underestimated. When the assumed period of LAIV immunity is nine months, the immunity period 287 
extends to the end of observation and the analysis relies heavily on non-vaccinated cases to 288 
estimate the weekly seasonal effects. However, there is no reason why seasonal effects should differ 289 
between vaccinated and unvaccinated cases.  290 
Third, we hypothesised that VE estimate would be highest during the months immediately following 291 
vaccination. Amoxicillin prescribing is a non-influenza specific outcome. The seasonal pattern of 292 
overall amoxicillin prescribing is not in alignment with that of influenza, whereas the seasonal 293 
pattern of prescribing attributable to influenza should be (with some lag). The burden due to 294 
influenza cannot be deciphered from the data and no method can disentangle the effect of waning 295 
vaccine immunity from the effect of other circulating viruses leading to amoxicillin prescriptions. 296 
Overall, our sensitivity analyses are useful in showing that effects beyond six months are protective, 297 
indicating that LAIV effectiveness is often long lasting throughout the season.  298 
Further, we found that restricting the observation period to weeks of active influenza circulation led 299 
to highly variable estimates of the VE estimates. Restricting the study period leads to a reduction in 300 
statistical power through three mechanisms. First, it reduces the number of cases included in the 301 
model, as highlighted in the footnote to Table 2. Second, restricting the study period will in this case 302 
mean that the ratio of exposed versus unexposed time is even larger, leading to a loss of efficiency. 303 
Third, restricting the study period will mean some vaccinated cases do not contribute any unexposed 304 
time to the model, meaning that the vaccine effects are estimated based on an even smaller number 305 
of children. Hence, restricting the study period led to much more variable estimates of VE and larger 306 
CIs, particularly for the 2013/14 season when the period of influenza circulation was shorter than in 307 
2014/15. We note that the CIs for Scenario 1 and the baseline scenario overlap in both seasons.  In 308 
the absence of reliable data on the duration of LAIV-induced immunity among children, the size of 309 
the effect of LAIV on amoxicillin prescribing should therefore not be overestimated. Ongoing 310 
monitoring of the effect of LAIV on amoxicillin prescribing in preschool children is required.  311 
Several other viruses, and in particular respiratory syncytial virus (RSV), is known to cause substantial 312 
morbidity in young children41 and may lead to amoxicillin prescribing. RSV circulation in the UK peaks 313 
in early December. Since we adjust for week of the winter season, this should not bias our results, as 314 
long as the incidence of RSV-related prescribing is the same in vaccinated and unvaccinated children. 315 
One small study has shown an increase in the risk of non-influenza respiratory viruses following IIV 316 
receipt,42 but these results have not been replicated for LAIV. The risk of bias caused by differential 317 
timing of RSV circulation in relation to influenza vaccination is therefore likely to be minimal.  318 
Our results add to a growing body of evidence showing a reduction in antibiotic prescribing 319 
associated with influenza vaccination.43 Universal influenza vaccination of children could contribute 320 
to the effort to decrease antibiotic prescribing in primary care, where three quarters of antibiotics 321 
are prescribed in the UK.44 Based on a simple calculation, we estimated that up to 5.6% of amoxicillin 322 
prescriptions could be prevented if LAIV uptake in two to four year old children in England had been 323 
50% rather than the observed 37.6%. More detailed studies are required to model the potential 324 
impact of increases in influenza vaccination uptake on antibiotic prescribing.  325 
We found a significantly reduced risk of amoxicillin prescribing during periods of influenza vaccine 326 
immunity in preschool children vaccinated with LAIV. Influenza vaccination of children may lead to 327 
reductions in amoxicillin prescribing, but the effect may be small. Further efforts should be made to 328 
increase uptake of LAIV in preschool children under the universal influenza vaccination programme.  329 
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Table 1. Characteristics of the children who had received amoxicillin prescriptions according to 449 
winter season  450 
 Winter season 
 2013/14 2014/15 
Variable n (%)  n (%) 
Age at start of season (years)   
2 8254 (53.1) 8475 (37.4) 
3 7289 (46.9) 7842 (34.6) 
4  6348 (28) 
Sex   
Male 8088 (52.0) 11613 (51.2) 
Female 7455 (48.0) 11052 (48.8) 
Vaccinated during the season   
No 9226 (59.4) 13272 (58.6) 
Yes – one dose 6162 (39.6) 9281 (41) 
Yes – two doses 155 (1.0) 112 (0.5) 
Clinical risk group   
No 14480 (93.2) 20801 (91.8) 
Yes 1063 (6.8) 1864 (8.2) 
Number of outcome episodes 
during season 
  
1 11648 (74.9) 17473 (77.1) 
2 2977 (19.2) 4088 (18) 
3 or more 918 (5.9) 1104 (4.9) 
Total N 15543 22665 
 451 
  452 
Table 2 Main model results and sensitivity analyses for influenza vaccine effectiveness (VE) in 453 
preventing amoxicillin prescriptions, according to season, with 95% confidence intervals (CI) 454 
 Winter season 
Analysis scenario 2013/14 2014/15 
Main analysis (baseline 
scenario) 
12.6% (6.7%, 18.2%) 
 
14.5% (9.6%, 19.2%) 
 
   
Sensitivity analyses   
Scenario 1: restricting to 
periods of active influenza 
circulation* 
4.2% (-47.4%, 37.7%) 
 
29.5% (13.9%, 42.3%) 
Scenario 2: Six month age 
groups 
12.5% (6.6%, 18.1%) 
 
14.4% (9.5%, 19.1%) 
Scenario 3: vaccine protection 
lasts for 9 months 
21.2% (14.9%, 27.1%) 
 
19.0% (13.7%, 24.0%) 
Scenario 4: two vaccination 
sub periods: 
  
14 days - <3 months 13.3% (6.8%, 19.2%) 13.9% (8.6%, 18.8%) 
3 - <6 months 11.9% (51%, 18.2%) 15.6% (10.0%, 20.9%) 
*Models include 7523 children in 2013/14 and 14616 children in 2014/15 455 
  456 
Figures  457 
Figure 1: Flowchart of the final selection of cases included in the SCCS analysis 458 
 459 
 460 
 461 
  462 
Figure 2. Cumulative proportion of cases in each cohort vaccinated and the number of amoxicillin 463 
prescriptions, by week of the study period† 464 
465 
†The shaded area shows period of active influenza circulation, and *indicates peak week of influenza circulation according 466 
to Public Health England sentinel swabbing schemes.27,34 467 
  468 
Supplementary file information  469 
 470 
- Supplementary Text S1: Deriving a formula for number of amoxicillin prescriptions given different 471 
vaccination uptake scenarios 472 
 473 
- Supplementary Figure S1. Influenza vaccine periods in the SCCS analyses for vaccinated and 474 
unvaccinated children 475 
 476 
- Supplementary Figure S2. Number of days between vaccination and amoxicillin prescription 477 
episodes among vaccinated amoxicillin prescription cases (numbers above the plot indicate the 478 
number of events per day in the specified time period)*  479 
 480 
*Note that x-axes for the two seasons are not the same 481 
 482 
- Supplementary Figure S3. Expected number of amoxicillin prescriptions in two to four year old 483 
children between September 2014 and April 2015 under varying scenarios of LAIV uptake. 484 
 485 
